2/9
04:05 pm
qncx
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
High
Report
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
2/3
07:12 am
qncx
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Maxim Group from a "strong-buy" rating to a "hold" rating.
High
Report
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Maxim Group from a "strong-buy" rating to a "hold" rating.
1/31
07:46 am
qncx
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Brookline Capital Management from a "strong-buy" rating to a "hold" rating.
High
Report
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Brookline Capital Management from a "strong-buy" rating to a "hold" rating.
1/31
07:46 am
qncx
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
High
Report
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
1/31
07:46 am
qncx
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Lucid Cap Mkts from a "strong-buy" rating to a "strong sell" rating.
High
Report
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Lucid Cap Mkts from a "strong-buy" rating to a "strong sell" rating.
1/30
07:00 am
qncx
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Citizens Jmp from an "outperform" rating to a "market perform" rating.
High
Report
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Citizens Jmp from an "outperform" rating to a "market perform" rating.
1/29
10:01 pm
qncx
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Citigroup Inc. from a "market outperform" rating to a "market perform" rating.
High
Report
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Citigroup Inc. from a "market outperform" rating to a "market perform" rating.
1/12
11:40 am
qncx
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential [Seeking Alpha]
High
Report
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential [Seeking Alpha]
1/6
08:02 am
qncx
Quince Therapeutics (NASDAQ:QNCX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Quince Therapeutics (NASDAQ:QNCX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
12/30
04:14 pm
qncx
Quince Therapeutics (NASDAQ:QNCX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Quince Therapeutics (NASDAQ:QNCX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/15
02:45 pm
qncx
Quince Therapeutics (NASDAQ:QNCX) had its price target raised by analysts at D. Boral Capital from $4.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Quince Therapeutics (NASDAQ:QNCX) had its price target raised by analysts at D. Boral Capital from $4.00 to $5.00. They now have a "buy" rating on the stock.
12/15
08:00 am
qncx
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
Medium
Report
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
12/10
04:56 pm
qncx
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders [Yahoo! Finance]
High
Report
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders [Yahoo! Finance]
12/10
04:05 pm
qncx
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
High
Report
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
11/24
08:00 am
qncx
Quince Therapeutics to Participate at Investor Events in December 2025
High
Report
Quince Therapeutics to Participate at Investor Events in December 2025
11/13
09:01 am
qncx
Quince Therapeutics (NASDAQ:QNCX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $4.00 price target on the stock.
Low
Report
Quince Therapeutics (NASDAQ:QNCX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $4.00 price target on the stock.
11/12
04:05 pm
qncx
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Low
Report
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results